Evidence map›Paper›PMID 40890582›Full record

ArticleThe journal of headache and pain2025

A nomogram for the prediction of response to anti-CGRP mAbs: the CGRP score.

Marina Romozzi, Ammar Lokhandwala, Catello Vollono, David García-Azorín, Giulia Vigani, Francesco De Cesaris, Claudia Altamura, Fabrizio Vernieri, Paolo Calabresi, Sonia Di Tella and 1 more

Abstract read
In one paragraph

Article in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Marina RomozziDipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy. marinaromozzi@gmail.com.
Ammar LokhandwalaDrexel University, Philadelphia, USA.
Catello VollonoDipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy.
David García-AzorínHeadache Unit, Department of Neurology, Hospital Universitario del Río Hortega, Valladolid, Valladolid, Spain.
Giulia ViganiSection of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
Francesco De CesarisSection of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
Claudia AltamuraUnità Cefalee e Neurosonologia, Fondazione Policlinico Campus Bio-Medico, Via Alvaro del Portillo, 200, Rome, Italy.
Fabrizio VernieriUnità Cefalee e Neurosonologia, Fondazione Policlinico Campus Bio-Medico, Via Alvaro del Portillo, 200, Rome, Italy.
Paolo CalabresiDipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy.
Sonia Di Tella *Dipartimento di Psicologia, Università Cattolica del Sacro Cuore, Milan, Italy.
Luigi Francesco Iannone *Digital and Predictive Medicine, Pharmacology, Clinical Metabolic Toxicology-Headache Center and Drug Abuse, AOU Policlinico di Modena, Modena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionReal-world studies have explored potential predictors of response to anti-calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs), though results have remained inconsistent. Machine learning (ML) algorithms are becoming increasingly relevant in migraine research, offering a data-driven approach to identifying predictors of response to preventive treatments. To maximize their potential, a clinically applicable and user-oriented framework is needed to promote the use of these algorithms in research and, eventually, as supportive tools in clinical practice.

methodsThis prospective cohort study included adults with migraine treated with anti-CGRP mAbs (anti-ligand and receptor) at two headache centers. Responders were defined as patients achieving ≥ 50% reduction in monthly headache days (MHDs) at 12 months. A logistic regression model was trained (80%) and tested (20%) using 11 baseline variables, including age, sex, migraine subtype, medication overuse, MHDs, and disability scores. Model performance was evaluated using accuracy, precision, recall, and F1-score. A nomogram was created for future research and clinical application. The model was then validated against an external test cohort treated with anti-CGRP mAbs.

resultsAmong 429 patients, 310 completed twelve months of treatment, with 236 (55.0%) classified as responders. The external test set included 109 patients. The ML model achieved an overall average weighted F1-score of 70.5% between the two test sets, with good performance in identifying “responders” (precision: 0.75, recall: 0.84, F1-score: 0.79). The model yielded predictions with an overall accuracy of 74% when tested against an external test cohort. Chronic migraine status, older age, and lower baseline MHDs were associated with higher response likelihood. Medication overuse and frequent analgesic use were negatively associated with response. The nomogram provided a clinically interpretable tool to estimate response probability, providing a total score named “CGRP Score” (CGRP mAbs Global Response Prediction).

conclusionThis ML-based predictive score achieved a good performance in identifying responders to anti-CGRP mAbs. The nomogram has the potential to be a practical, user-friendly tool for supporting clinical decision-making after validation.

Indexed as

Antibodies, MonoclonalCalcitonin Gene-Related PeptideMigraine DisordersNomogramsAdultFemaleHumansMachine LearningMaleMiddle AgedPrediction AlgorithmsPredictive Learning ModelsProspective StudiesTreatment OutcomeAntibodies, MonoclonalCalcitonin Gene-Related PeptideCalcitonin gene-related peptideMachine-learningMigraineMonoclonal antibodiesPredictorsResponse

Identifiers

PMID40890582
PMCPMC12403356

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.